JP2017527274A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527274A5
JP2017527274A5 JP2017504103A JP2017504103A JP2017527274A5 JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5 JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5
Authority
JP
Japan
Prior art keywords
binding molecule
seq
sequence
bispecific binding
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504103A
Other languages
English (en)
Japanese (ja)
Other versions
JP6871155B2 (ja
JP2017527274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/041989 external-priority patent/WO2016014942A1/en
Publication of JP2017527274A publication Critical patent/JP2017527274A/ja
Publication of JP2017527274A5 publication Critical patent/JP2017527274A5/ja
Application granted granted Critical
Publication of JP6871155B2 publication Critical patent/JP6871155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504103A 2014-07-25 2015-07-24 二重特異性her2及びcd3結合分子 Active JP6871155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
US62/029,342 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (3)

Publication Number Publication Date
JP2017527274A JP2017527274A (ja) 2017-09-21
JP2017527274A5 true JP2017527274A5 (Direct) 2018-10-18
JP6871155B2 JP6871155B2 (ja) 2021-05-12

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504103A Active JP6871155B2 (ja) 2014-07-25 2015-07-24 二重特異性her2及びcd3結合分子

Country Status (15)

Country Link
US (2) US10519248B2 (Direct)
EP (1) EP3172236B1 (Direct)
JP (1) JP6871155B2 (Direct)
KR (1) KR102638104B1 (Direct)
CN (1) CN107124884B (Direct)
AU (1) AU2015292374B2 (Direct)
BR (1) BR112017001513A2 (Direct)
CA (1) CA2956014C (Direct)
ES (1) ES2832704T3 (Direct)
IL (1) IL250249B (Direct)
MX (1) MX386342B (Direct)
RU (1) RU2017105849A (Direct)
SG (1) SG11201700506TA (Direct)
WO (1) WO2016014942A1 (Direct)
ZA (1) ZA201701341B (Direct)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201809385RA (en) 2013-12-17 2018-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
RU2017105849A (ru) 2014-07-25 2018-08-29 Мемориал Слоан Кеттеринг Кэнсер Сентер Биспецифические молекулы, связывающие her2 и cd3
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック, インコーポレイテッド 抗cd3抗体及び使用方法
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CA3051484A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
WO2018200562A1 (en) * 2017-04-24 2018-11-01 Memorial Sloan Kettering Cancer Center Anti-cd33 antibody agents
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
AU2019234468B2 (en) * 2018-03-12 2026-01-15 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
CN111527108A (zh) * 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
EP3774900A1 (en) * 2018-04-13 2021-02-17 F. Hoffmann-La Roche AG Her2-targeting antigen binding molecules comprising 4-1bbl
US12473360B2 (en) 2018-06-14 2025-11-18 Bioatla, Inc. Multi-specific antibody constructs
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业(上海)股份有限公司 抗her2/pd1双特异性抗体
CA3121168A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
EP3894601A4 (en) * 2018-12-11 2023-01-11 The Translational Genomics Research Institute IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT
US12441793B2 (en) * 2019-02-22 2025-10-14 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN114341176A (zh) * 2019-04-08 2022-04-12 纪念斯隆凯特琳癌症中心 Cd19抗体及其使用方法
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113874399B (zh) * 2019-05-23 2025-07-11 维洛斯生物股份有限公司 抗ror1/抗cd3双特异性结合分子
US20220251192A1 (en) * 2019-06-26 2022-08-11 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US20230270857A1 (en) * 2020-07-28 2023-08-31 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック, インコーポレイテッド 抗cd20/抗cd3二重特異性抗体の皮下投薬
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
MX2023006395A (es) 2020-12-03 2023-06-15 Century Therapeutics Inc Celulas dise?adas geneticamente y usos de estas.
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
TW202310871A (zh) 2021-05-14 2023-03-16 美商建南德克公司 用莫蘇妥珠單抗及帕羅托珠單抗維多汀治療cd20陽性增生性失調之方法
WO2023014810A2 (en) * 2021-08-04 2023-02-09 Abpro Corporation Anti-her2 antibodies and uses thereof
WO2023069341A2 (en) * 2021-10-20 2023-04-27 Memorial Sloan Kettering Cancer Center Anti-tshr multi-specific antibodies and uses thereof
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
JP7579481B2 (ja) 2022-04-13 2024-11-07 ジェネンテック, インコーポレイテッド モスネツズマブの医薬組成物および使用方法
WO2024163964A2 (en) * 2023-02-04 2024-08-08 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
TW202532440A (zh) 2023-10-19 2025-08-16 美商建南德克公司 用於治療HER2陽性癌症的IL15/IL15Rα異二聚體FC融合蛋白及HER2xCD3雙特異性抗體之組合

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
EP2155783B2 (en) 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
ES2589769T3 (es) 2009-02-27 2016-11-16 Massachusetts Institute Of Technology Proteínas modificadas con alta afinidad por quelatos de DOTA
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
CN103347894B (zh) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 抗gd2抗体
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
BR112013028907A2 (pt) * 2011-05-08 2017-01-31 Legochem Biosciences Inc conjugados de proteína-agente ativo e método para preparar os mesmos
US11492383B2 (en) * 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013065869A1 (en) * 2011-11-02 2013-05-10 Ajinomoto Co.,Inc. Method for secretory production of protein
EP3786183A3 (en) * 2012-06-15 2021-06-09 Imaginab, Inc. Antigen binding constructs to cd3
CN112079929A (zh) * 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
EP4067383A1 (en) * 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
FI3083686T4 (fi) 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
RU2017105849A (ru) 2014-07-25 2018-08-29 Мемориал Слоан Кеттеринг Кэнсер Сентер Биспецифические молекулы, связывающие her2 и cd3
AU2016219534B2 (en) 2015-02-09 2021-07-01 Massachusetts Institute Of Technology Multi-specific antibodies with affinity for human A33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Similar Documents

Publication Publication Date Title
JP2017527274A5 (Direct)
RU2017105849A (ru) Биспецифические молекулы, связывающие her2 и cd3
Lou et al. Antibody variable region engineering for improving cancer immunotherapy
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
JP2020063262A5 (Direct)
Marvin et al. Recombinant approaches to IgG‐like bispecific antibodies
JP2017520575A5 (Direct)
Chen et al. Bispecific antibodies in cancer immunotherapy
JP2019524693A5 (Direct)
JP2013527761A5 (Direct)
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2020501531A5 (Direct)
JP2018503380A5 (Direct)
JP2018507188A5 (Direct)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
WO2013044215A4 (en) Vegf/dll4 binding agents and uses thereof
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
RU2022102446A (ru) Биспецифические связывающие белки и пути их применения
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2019500011A5 (Direct)
WO2018119118A4 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
IL276903B1 (en) Bispecific egfr/cd16 antigen-binding protein
JP2012519492A5 (Direct)